Skip to main navigation
Skip to search
Skip to main content
Utrecht University Home
Help & FAQ
Home
People
Research units
Research output
Activities
In the media
Prizes & Grants
Search by expertise, name or affiliation
Endocrine therapy for breast cancer patients in South Africa
Y. Taghipour Bazargani
,
Anthonius De Boer
,
Hubertus G.M. Leufkens
,
Aukje K. Mantel-Teeuwisse
Dept of Pharmaceutical Sciences
Pharmacoepidemiology and Clinical Pharmacology
Research output
:
Contribution to journal
›
Meeting Abstract
›
Other research output
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Endocrine therapy for breast cancer patients in South Africa'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Endocrine Therapy
100%
Breast Cancer Patients
100%
South Africa
100%
Aromatase Inhibitors
100%
Postmenopausal Patients
66%
Premenopausal Patients
33%
ER+ Breast Cancer
33%
Treatment Duration
16%
Recurrence Risk
16%
Realistic Scenario
16%
Healthcare Database
16%
South African
16%
Utilization Rate
16%
Risk of Death
16%
Actual Use
16%
Patient Treatment
16%
Disease Stage
16%
Treatment Combination
16%
Estrogen Receptor-positive Breast Cancer
16%
Access to Treatment
16%
Estrogen Receptor-positive
16%
Middle-income Countries
16%
IMS Health
16%
Sales Data
16%
Inhibitor-1
16%
Registry Report
16%
Menopausal Status
16%
ER +
16%
National Cancer Registry
16%
Estimated numbers
16%
Annual Sale
16%
Data Access
16%
Number of Patients
16%
Medicine and Dentistry
Breast Cancer
100%
Hormone Therapy
100%
Tamoxifen
100%
Aromatase Inhibitor
85%
Medicine
28%
Recurrent Disease
14%
Estrogen Receptor Positive Breast Cancer
14%
Cancer Registry
14%
Estrogen Receptor
14%
Diseases
14%
Pharmacology, Toxicology and Pharmaceutical Science
Endocrine Therapy
100%
Tamoxifen
100%
Breast Cancer
100%
Aromatase Inhibitor
85%
Cancer Registry
14%
Estrogen Receptor
14%
Recurrent Disease
14%
Estrogen Receptor Positive Breast Cancer
14%
Diseases
14%
Agricultural and Biological Sciences
Tamoxifen
100%
Aromatase
85%
Estrogen Receptor
28%